Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.

Fichtenbaum CJ, Evans SE, Aberg JA.

AIDS. 2011 Oct 23;25(16):2053. doi: 10.1097/QAD.0b013e32834b9680. No abstract available.

2.

High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors.

Aslangul E, Fellahi S, Assoumou LK, Bastard JP, Capeau J, Costagliola D.

AIDS. 2011 May 15;25(8):1128-31. doi: 10.1097/QAD.0b013e328346be29.

PMID:
21422984
3.

Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.

Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, Fiévet MH, Boccara F, Bonnefont-Rousselot D, Melchior JC, Giral P, Costagliola D.

AIDS. 2010 Jan 2;24(1):77-83. doi: 10.1097/QAD.0b013e328331d2ab.

PMID:
19838098
6.
7.

Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study.

Kai T, Arima S, Taniyama Y, Nakabou M, Kanamasa K.

Clin Exp Hypertens. 2008 Oct;30(7):530-40. doi: 10.1080/10641960802251925.

PMID:
18855257
8.

Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.

Negredo E, Moltó J, Puig J, Cinquegrana D, Bonjoch A, Pérez-Alvarez N, López-Blázquez R, Blanco A, Clotet B, Rey-Joly C.

AIDS. 2006 Nov 14;20(17):2159-64.

PMID:
17086055
9.

Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.

Benesic A, Zilly M, Kluge F, Weissbrich B, Winzer R, Klinker H, Langmann P.

Infection. 2004 Aug;32(4):229-33.

PMID:
15293079
10.

Effect of atorvastatin and pravastatin on serum C-reactive protein.

Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Taylor AJ.

Am Heart J. 2003 Feb;145(2):e8.

PMID:
12595863
11.

Effects of switching pravastatin to cerivastatin on C-reactive protein, butyrylcholinesterase, and lipids.

Shinn AH, Carr-Lopez SM, Smith JW, Elledge EA, Smith TJ.

Curr Med Res Opin. 2005 Feb;21(2):207-14.

PMID:
15801991
12.

Evaluation and pharmacologic management of the HIV-infected patient with dyslipidemia.

Hardwicke RL, Lewis ST, Grimes RM.

J Assoc Nurses AIDS Care. 2010 Sep-Oct;21(5):429-38. doi: 10.1016/j.jana.2009.12.006. Epub 2010 Mar 19.

PMID:
20303794
13.

Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor.

Bittar R, Giral P, Aslangul E, Assoumou L, Valantin MA, Kalmykova O, Federspiel MC, Cherfils C, Costagliola D, Bonnefont-Rousselot D; French National Agency for AIDS and Viral Hepatitis Research (ANRS) 126 study group.

AIDS. 2012 Sep 10;26(14):1801-5.

PMID:
22739396
14.

The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.

Albert MA, Staggers J, Chew P, Ridker PM; PRINCE Investigators.

Am Heart J. 2001 Jun;141(6):893-8.

PMID:
11376301
15.

Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir.

de Kanter CT, Keuter M, van der Lee MJ, Koopmans PP, Burger DM.

Antivir Ther. 2011;16(3):435-7. doi: 10.3851/IMP1747.

PMID:
21555828
16.

[The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia].

Broncel M, Koter-Michalak M, Chojnowska-Jezierska J.

Przegl Lek. 2006;63(9):738-42. Polish.

PMID:
17479860
17.

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.

Martínez E, D'Albuquerque PM, Llibre JM, Gutierrez F, Podzamczer D, Antela A, Berenguer J, Domingo P, Moreno X, Perez I, Pich J, Gatell JM; SPIRAL Trial Group.

AIDS. 2012 Nov 28;26(18):2315-26. doi: 10.1097/QAD.0b013e328359f29c.

PMID:
23018438
18.

Statins in HIV-associated lipodystrophy and metabolic syndrome: is there a missing link?

Gharakhanian S, Boccara F, Capeau J.

AIDS. 2006 Apr 24;20(7):1061-3. No abstract available.

PMID:
16603860
19.

[C-reactive protein in cardiovascular diseases].

Lubas W, Gutkowski K.

Przegl Lek. 2006;63(7):562-6. Review. Polish.

PMID:
17203810
20.

Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.

Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323.

PMID:
18294112
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk